10x Genomics (TXG) Equity Average (2018 - 2025)
10x Genomics (TXG) has disclosed Equity Average for 8 consecutive years, with $790.7 million as the latest value for Q4 2025.
- Quarterly Equity Average rose 10.36% to $790.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $790.7 million through Dec 2025, up 10.36% year-over-year, with the annual reading at $753.2 million for FY2025, 3.81% up from the prior year.
- Equity Average hit $790.7 million in Q4 2025 for 10x Genomics, up from $779.2 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $812.1 million in Q1 2022 to a low of $708.5 million in Q1 2025.
- Historically, Equity Average has averaged $765.9 million across 5 years, with a median of $774.2 million in 2023.
- Biggest five-year swings in Equity Average: soared 92.05% in 2021 and later decreased 9.58% in 2024.
- Year by year, Equity Average stood at $808.9 million in 2021, then decreased by 2.24% to $790.8 million in 2022, then decreased by 6.02% to $743.1 million in 2023, then fell by 3.59% to $716.5 million in 2024, then rose by 10.36% to $790.7 million in 2025.
- Business Quant data shows Equity Average for TXG at $790.7 million in Q4 2025, $779.2 million in Q3 2025, and $740.1 million in Q2 2025.